Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03298451
Recruitment Status : Recruiting
First Posted : October 2, 2017
Last Update Posted : November 29, 2021
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Actual Primary Completion Date : August 27, 2021
Estimated Study Completion Date : April 30, 2023